KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash & Equivalents (2016 - 2025)

Amgen (AMGN) has 17 years of Cash & Equivalents data on record, last reported at $9.4 billion in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 4.82% year-over-year to $9.4 billion; the TTM value through Sep 2025 reached $9.4 billion, up 4.82%, while the annual FY2024 figure was $12.0 billion, 9.4% up from the prior year.
  • Cash & Equivalents reached $9.4 billion in Q3 2025 per AMGN's latest filing, up from $8.0 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $34.7 billion in Q3 2023 and bottomed at $5.2 billion in Q2 2022.
  • Average Cash & Equivalents over 5 years is $13.0 billion, with a median of $9.0 billion recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 557.31% in 2023, then plummeted 74.03% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $8.0 billion in 2021, then dropped by 4.51% to $7.6 billion in 2022, then soared by 43.45% to $10.9 billion in 2023, then rose by 9.4% to $12.0 billion in 2024, then dropped by 21.11% to $9.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $9.4 billion in Q3 2025, $8.0 billion in Q2 2025, and $8.8 billion in Q1 2025.